See the DrugPatentWatch profile for tigecycline

Based on the available information, there is limited research directly examining the impact of age on liver risk associated with the use of tigecycline. However, it is known that tigecycline, like many other antibiotics, is metabolized in the liver [1]. As a result, age-related changes in liver function could potentially impact the safety and efficacy of tigecycline treatment.

Elderly patients are more likely to have reduced liver function due to the natural aging process and the increased prevalence of liver diseases in this population [2]. Therefore, it is plausible that older adults may be at greater risk of liver-related adverse effects when taking tigecycline. However, this hypothesis requires further investigation.

A study published in the Journal of Antimicrobial Chemotherapy analyzed the safety and efficacy of tigecycline in various patient populations, including elderly patients [3]. The authors noted that tigecycline was generally well-tolerated, with a similar adverse event profile across different age groups. However, this study did not specifically focus on liver-related adverse events.

In summary, while age-related changes in liver function may potentially impact the safety of tigecycline use, there is a lack of direct evidence on the relationship between age and liver risk associated with tigecycline. Healthcare providers should consider age-related changes in liver function when prescribing tigecycline, particularly in elderly patients. Further research is needed to better understand the impact of age on the liver risk associated with tigecycline use.

Sources:

1. DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/drugs/tigecycline>
2. National Institute on Aging. (2017). Aging Changes in the Liver. Retrieved from <https://www.nia.nih.gov/health/aging-changes-liver>
3. Giamarellou, H., Antoniadou, A., & Falagas, M. E. (2008). Safety and efficacy of tigecycline: a systematic review. Journal of Antimicrobial Chemotherapy, 62(3), 451-461. doi: 10.1093/jac/dkn001